aap

1 - 12 of 23
Sort by: popularity | newest
Page  2  of 2 | Next
aap Implantate

Progression to a pure trauma player

QuickView | Pharmaceutical & healthcare | 24 May 2016

aap Implantate is undergoing a strategic transition to being a pure trauma company and Q1 results, which were within guidance, set the scene for the group in its new shape. The completed sale of its biomaterials business (based on an assumed enterprise value of €36m), a drive to growth in Western Europe and the US and cost reshaping should support management's guidance of 20% growth in trauma products and sales in the continued operation of €13-15m in FY16.

aap Implantate

Termination of coverage

Termination | Pharmaceutical & healthcare | 16 May 2018

Edison Investment Research is terminating coverage on aap Implantate (AAQ). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

aap Implantate

Preliminary FY17 sales in line with guidance

QuickView | Pharmaceutical & healthcare | 21 Feb 2018

aap Implantate's preliminary FY17 results show an encouraging 20% y-o-y growth in trauma revenues, with the strongest performance coming from the North American distribution business. Management has guided to continued revenue growth and reducing EBITDA losses in FY18. Delivery on key partnerships and the commercialisation of the silver-coating technology are the main stepping points to eventual profitability. The near-term goal for aap is to start the human clinical trial for the silver-coating technology with the aim of reaching CE and FDA approval.

aap Implantate

Focus is the key foundation

QuickView | Pharmaceutical & healthcare | 28 Nov 2017

aap Implantate’s recent results for Q317 and the first nine months of 2017 (9M17) justified its recent trauma focus with 11% and 13% increases in trauma sales, respectively. With investments in the Quality First initiative, the evaluation of strategic options and the share buyback, it was pleasing to see that sales and EBITDA (loss) continue to be expected within the guidance range for the full year, albeit towards the lower end of the range.

aap Implantate

Exploring strategic alternatives to add value

QuickView | Pharmaceutical & healthcare | 17 Aug 2017

aap Implantate announced its H1 results with a 5% increase in l-f-l sales to EUR 5.4m. This increase was predominantly due to a reported 14% Trauma sales growth in H1 despite Q2 Trauma sales remaining flat versus the previous year’s EUR 2.3m, though still broadly in line with management’s expectations. H1 positives include growth in established markets where aap Implantate has focused initiatives to drive sales (North America +26% and DACH region +10%). Traction in these markets (Europe and the US) remains key to a sustained return to growth.

aap Implantate

Solid start to 2017

QuickView | Pharmaceutical & healthcare | 18 May 2017

aap Implantate has announced a solid start to 2017 with Q1 trauma sales increasing by 30% to €2.9m and total sales up 23% to €3.1m, slightly ahead of company guidance of €1.8m to €2.8m. This is significant as 2017 is the first year following the company's transformation into a pure trauma player and suggests that traction is starting to develop following initiatives to drive sales in the established markets. Increasing market penetration in Europe and the US remains key to a sustained return to growth.

aap Implantate

Time to capitalise on its core focus - trauma

QuickView | Pharmaceutical & healthcare | 06 Apr 2017

aap Implantate announced that it successfully completed its transformation to a pure trauma player in 2016. The company reported challenging FY16 results that were below management's original expectations, but broadly in line with the revised guidance, with sales from its continuing operations down 15% y-o-y to €10.5m. However, this was not wholly unexpected as the company has undergone a strategic transition to being a pure trauma-focused company. Increasing market penetration in Europe and the US will be key to a successful return to growth.

aap Implantate

Progression of LOQTEQ portfolio

QuickView | Pharmaceutical & healthcare | 21 Nov 2016

Q316 results highlighted a challenging quarter despite being broadly in line with company guidance (sales of €2.9m and an EBITDA loss of €1.8m). However, US sales were above company expectations (Q3: €0.7m, 9M: €2.0m) and are indicative that the initiatives put in place to drive sales in more established markets are beginning to prove fruitful. aap Implantate will need a solid Q4 to deliver on its FY16 revenue guidance, which it now expects to be at the lower end (€13.0-15.0m).

aap Implantate

Continuing to execute strategy on core focus

QuickView | Pharmaceutical & healthcare | 09 Nov 2016

Q216 results were in line with the upper end of company guidance, withsales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues tofocus on its strategic transition to a pure trauma company following therecent sale of its Biomaterials business. As the company continues todrive sales of LOQTEQ in Western Europe and the US alongside theimplementation of cost reduction measures, we could see a return tosustained growth.

aap Implantate

Continuing to execute strategy on core focus

QuickView | Pharmaceutical & healthcare | 03 Oct 2016

Q216 results were in line with the upper end of company guidance, with sales of EUR 3.4m and an EBITDA loss of EUR 1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.

aap Implantate

NO SUBTITLE

QuickView | Pharmaceutical & healthcare | 13 Sep 2016

Q216 results were in line with the upper end of company guidance, with sales of EUR 3.4m and an EBITDA loss of EUR 1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.

aap Implantate

Continuing to execute strategy on core focus

QuickView | Pharmaceutical & healthcare | 07 Sep 2016

Q216 results were in line with the upper end of company guidance, with sales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.